Summary of MDR Analysis
| . | Immunophenotype . | MDR1 (RT-PCR) . | Pgp (MRK16) . | Rhodamine Efflux . |
|---|---|---|---|---|
| Case no. 1 | sCD3−, CD8+, CD56+ | +++ | 30% | 86% |
| Case no. 2 | sCD3−, CD4+, CD56+ | + | 0% | 0% |
| Case no. 3 | sCD3−, CD4−, CD8−, CD56+ | ++++ | 49% | 73% |
| . | Immunophenotype . | MDR1 (RT-PCR) . | Pgp (MRK16) . | Rhodamine Efflux . |
|---|---|---|---|---|
| Case no. 1 | sCD3−, CD8+, CD56+ | +++ | 30% | 86% |
| Case no. 2 | sCD3−, CD4+, CD56+ | + | 0% | 0% |
| Case no. 3 | sCD3−, CD4−, CD8−, CD56+ | ++++ | 49% | 73% |
MDR analysis is performed using RT-PCR for MDR1 mRNA expression in comparison with β2-microglobulin RNA level; Pgp is determined by flow cytometry with MRK16 MoAb. Rhodamine efflux is a flow cytometry assay previously described.